nach oben

Current Infectious Disease Reports

Erschienen in:

01.01.2016 | Respiratory Infections (F Arnold, Section Editor)

The Impact of Prior Antibiotic Therapy on Outcomes in Children Hospitalized for Community-Acquired Pneumonia

verfasst von: Eran Lavi, Oded Breuer

Erschienen in: Current Infectious Disease Reports | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Here, we review current available literature regarding the effect of prior antibiotic treatment on outcomes of children hospitalized for community-acquired pneumonia (CAP). To date, no prospective trial has reported information regarding morbidity or mortality in this group of patients. Retrospective studies have provided evidence for the advantage of treatment with broad-spectrum antibiotics in children who failed prior antibiotic therapy. We discuss the changing epidemiology of CAP in the post PCV13 and Hib vaccines era and its relevance to the outcome of pediatric patients hospitalized for CAP. Current studies still report Streptococcus pneumoniae as the most common typical bacterial causative agent in pediatric CAP. However, in children who fail to respond to guideline directed antibiotic therapy, a non-pneumococcal, possibly one of several β-lactam resistant causative bacterial agents should be considered thus clarifying the advantage for broad-spectrum empirical antibiotic treatment in this group of patients.

1.•

Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381(9875):1405–16. Global epidemilogical data regarding childhood pneumonia.PubMedCrossRef

Lee GE, Lorch SA, Sheffler-Collins S, Kronman MP, Shah SS. National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics. 2010;126(2):204–13.PubMedPubMedCentralCrossRef

3.••

Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372(9):835–45. Updated data on pediatric community aquired pneumonia hospitalization in the U.S..PubMedCrossRefPubMedCentral

Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113(4):701–7.PubMedCrossRef

Lahti E, Peltola V, Waris M, Virkki R, Rantakokko-Jalava K, Jalava J, et al. Induced sputum in the diagnosis of childhood community-acquired pneumonia. Thorax. 2009;64(3):252–7.PubMedCrossRef

Blaschke AJ, Heyrend C, Byington CL, Obando I, Vazquez-Barba I, Doby EH, et al. Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyema. Pediatr Infect Dis J. 2011;30(4):289–94.PubMedPubMedCentralCrossRef

Juven T, Mertsola J, Toikka P, Virkki R, Leinonen M, Ruuskanen O. Clinical profile of serologically diagnosed pneumococcal pneumonia. Pediatr Infect Dis J. 2001;20(11):1028–33.PubMedCrossRef

Juven T, Mertsola J, Waris M, Leinonen M, Meurman O, Roivainen M, et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J. 2000;19(4):293–8.PubMedCrossRef

Claesson BA, Lagergard T, Trollfors B. Antibody response to outer membrane of noncapsulated Haemophilus influenzae isolated from the nasopharynx of children with pneumonia. Pediatr Infect Dis J. 1991;10(2):104–8.PubMedCrossRef

10.

Isaacs D. Problems in determining the etiology of community-acquired childhood pneumonia. Pediatr Infect Dis J. 1989;8(3):143–8.PubMed

11.

Gendrel D, Raymond J, Moulin F, Iniguez JL, Ravilly S, Habib F, et al. Etiology and response to antibiotic therapy of community-acquired pneumonia in French children. Eur J Clin Microbiol Infect Dis: Off Publ Eur Soc Clin Microbiol. 1997;16(5):388–91.CrossRef

12.••

Lodha R, Kabra SK, Pandey RM. Antibiotics for community-acquired pneumonia in children. Cochrane Database Syst Rev. 2013;6, CD004874. Treatment guidelines for pediatric community aquired pneumonia.PubMed

13.••

Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011;66 Suppl 2:ii1–23. Treatment guidelines for pediatric community aquired pneumonia.PubMedCrossRef

14.••

Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2011;53(7):e25–76. Treatment guidelines for pediatric community aquired pneumonia.CrossRef

15.

Dellit TH, Owens RC, McGowan Jr JE, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2007;44(2):159–77.CrossRef

16.

FDA. FDA approves pneumococcal disease vaccine with broader protection 2010 [updated 04/24/2013 cited 2015 14 June]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm201758.htm.

17.

Advisory Committee on Immunization P. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and reports : Morbidity and mortality weekly report Recommendations and reports / Centers for Disease Control. 2000 Oct 6;49(RR-9):1–35. PubMed.

18.

Nuorti JP, Whitney CG, Centers for Disease C, Prevention. Prevention of pneumococcal disease among infants and children—use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports / Centers for Disease Control. 2010 Dec 10;59(RR-11):1–18. PubMed

19.

Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348(18):1737–46.PubMedCrossRef

20.

Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41.PubMedCrossRef

21.

Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369(9568):1179–86.PubMedCrossRef

22.

Simonsen L, Taylor RJ, Young-Xu Y, Haber M, May L, Klugman KP. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio. 2011;2(1):e00309–10.PubMedPubMedCentralCrossRef

23.

Spratt BG, Greenwood BM. Prevention of pneumococcal disease by vaccination: does serotype replacement matter? Lancet. 2000;356(9237):1210–1.PubMedCrossRef

24.

Lipsitch M. Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci U S A. 1997;94(12):6571–6.PubMedPubMedCentralCrossRef

25.

Harboe ZB, Dalby T, Weinberger DM, Benfield T, Molbak K, Slotved HC, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2014;59(8):1066–73.CrossRef

26.

Becker-Dreps S, Amaya E, Liu L, Moreno G, Rocha J, Briceno R, et al. Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua. Pediatr Infect Dis J. 2014;33(6):637–42.PubMedCrossRef

27.

Simonsen L, Taylor RJ, Schuck-Paim C, Lustig R, Haber M, Klugman KP. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis. Lancet Respir Med. 2014;2(5):387–94.PubMedCrossRef

28.

Waight PA, Andrews NJ, Ladhani NJ, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(6):629.PubMedCrossRef

29.

Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354(14):1455–63.PubMedCrossRef

30.

Moore CE, Paul J, Foster D, Mahar SA, Griffiths D, Knox K, et al. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. Journal Infect Dis. 2014;210(7):1001–11.CrossRef

31.

Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–9.PubMedCrossRef

32.

Sinaniotis CA, Sinaniotis AC. Community-acquired pneumonia in children. Curr Opin Pulm Med. 2005;11(3):218–25.PubMedCrossRef

33.

Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2009;48(11):1596–600.CrossRef

34.

Bradley JS, Garonzik SM, Forrest A, Bhavnani SM. Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose to treat an infection. Pediatr Infect Dis J. 2010;29(11):1043–6.PubMedCrossRef

35.

Dagan R, Hoberman A, Johnson C, Leibovitz EL, Arguedas A, Rose FV, et al. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J. 2001;20(9):829–37.PubMedCrossRef

36.

Friedland IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J. 1995;14(10):885–90.PubMedCrossRef

37.

Aurangzeb B, Hameed A. Comparative efficacy of amoxicillin, cefuroxime and clarithromycin in the treatment of community-acquired pneumonia in children. J Coll Physicians Surg Pak: JCPSP. 2003;13(12):704–7.PubMed

38.

Vuori-Holopainen E, Peltola H, Kallio MJ, Group S-TS. Narrow- versus broad-spectrum parenteral anatimicrobials against common infections of childhood: a prospective and randomised comparison between penicillin and cefuroxime. Eur J Pediatr. 2000;159(12):878–84.PubMedCrossRef

39.

Klein M. Multicenter trial of cefpodoxime proxetil vs. amoxicillin-clavulanate in acute lower respiratory tract infections in childhood. International Study Group. Pediatr Infect Dis J. 1995;14(4 Suppl):S19–22.PubMedCrossRef

40.

Amir J, Harel L, Eidlitz-Markus T, Varsano I. Comparative evaluation of cefixime versus amoxicillin-clavulanate following ceftriaxone therapy of pneumonia. Clin Pediatr. 1996;35(12):629–33.CrossRef

41.

Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282(15):1458–65.PubMedCrossRef

42.

Nathwani D, Williams F, Winter J, Winter J, Ogston S, Davey P. Use of indicators to evaluate the quality of community-acquired pneumonia management. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2002;34(3):318–23.

43.

Levy G, Perez M, Rodriguez B, Hernandez Voth A, Perez J, Gnoni M, et al. Adherence with national guidelines in hospitalized patients with community-acquired pneumonia: results from the CAPO study in Venezuela. Arch Bronconeumol. 2015;51(4):163–8.PubMedCrossRef

44.

Chenoweth CE, Saint S, Martinez F, Lynch 3rd JP, Fendrick AM. Antimicrobial resistance in Streptococcus pneumoniae: implications for patients with community-acquired pneumonia. Mayo Clin Proc. 2000;75(11):1161–8.PubMedCrossRef

45.

De Schutter I, De Wachter E, Crokaert F, Verhaegen J, Soetens O, Pierard D, et al. Microbiology of bronchoalveolar lavage fluid in children with acute nonresponding or recurrent community-acquired pneumonia: identification of nontypeable Haemophilus influenzae as a major pathogen. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2011;52(12):1437–44.CrossRef

46.

Van Eldere J, Slack MP, Ladhani S, Cripps AW. Non-typeable Haemophilus influenzae, an under-recognised pathogen. Lancet Infect Dis. 2014;14(12):1281–92.PubMedCrossRef

47.•

Ladhani S, Slack MP, Heath PT, von Gottberg A, Chandra M, Ramsay ME, et al. Invasive Haemophilus influenzae disease, Europe, 1996–2006. Emerg Infect Dis. 2010;16(3):455–63. Review regarding invasive haemophilus influenza disease in europe.PubMedPubMedCentralCrossRef

48.

Giufre M, Cardines R, Caporali MG, Accogli M, D’Ancona F, Cerquetti M. Ten years of Hib vaccination in Italy: prevalence of non-encapsulated Haemophilus influenzae among invasive isolates and the possible impact on antibiotic resistance. Vaccine. 2011;29(22):3857–62.PubMedCrossRef

49.

MacNeil JR, Cohn AC, Farley M, Mair R, Baumbach J, Bennett N, et al. Current epidemiology and trends in invasive Haemophilus influenzae disease—United States, 1989–2008. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2011;53(12):1230–6.CrossRef

50.

Pirez MC, Algorta G, Chamorro F, Romero C, Varela A, Cedres A, et al. Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and haemophilus influenzae type b conjugate vaccine in a Pediatric Referral Hospital in Uruguay. Pediatr Infect Dis J. 2014;33(7):753–9.PubMedCrossRef

51.

Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M, Biscardi S, et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2014;58(7):918–24.CrossRef

52.

Deeks SL, Palacio R, Ruvinsky R, Kertesz DA, Hortal M, Rossi A, et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group. Pediatrics. 1999;103(2):409–13.PubMedCrossRef

53.

Alpuche C, Garau J, Lim V. Global and local variations in antimicrobial susceptibilities and resistance development in the major respiratory pathogens. Int J Antimicrob Agents. 2007;30 Suppl 2:S135–8.PubMedCrossRef

54.

Beekmann SE, Heilmann KP, Richter SS, Garcia-de-Lomas J, Doern GV, Group GS. Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002–2003. Results of the multinational GRASP surveillance program. Int J Antimicrob Agents. 2005;25(2):148–56.PubMedCrossRef

55.

Cohen R, Bingen E, Levy C, Benani M, Thollot F, Klink Z, et al. Antibiotic resistance of pneumococci and H. influenzae isolated from the nasopharyngeal flora of children with acute otitis media between 2006 and 2010. Arch Pediatrie: Organe Off Soc Fr Pediatrie. 2011;18(8):926–31. PubMed Resistance aux antibiotiques des pneumocoques et H. influenzae isoles de la flore rhinopharyngee d’enfants presentant une otite moyenne aigue entre 2006 et 2010.CrossRef

56.

Resman F, Ristovski M, Forsgren A, Kaijser B, Kronvall G, Medstrand P, et al. Increase of beta-lactam-resistant invasive Haemophilus influenzae in Sweden, 1997 to 2010. Antimicrob Agents Chemother. 2012;56(8):4408–15.PubMedPubMedCentralCrossRef

57.

Sill ML, Tsang RS. Antibiotic susceptibility of invasive Haemophilus influenzae strains in Canada. Antimicrob Agents Chemother. 2008;52(4):1551–2.PubMedPubMedCentralCrossRef

58.

Hotomi M, Fujihara K, Billal DS, Suzuki K, Nishimura T, Baba S, et al. Genetic characteristics and clonal dissemination of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae strains isolated from the upper respiratory tract of patients in Japan. Antimicrob Agents Chemother. 2007;51(11):3969–76.PubMedPubMedCentralCrossRef

59.

Garcia-Cobos S, Campos J, Lazaro E, Roman F, Cercenado E, Garcia-Rey C, et al. Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime. Antimicrob Agents Chemother. 2007;51(7):2564–73.PubMedPubMedCentralCrossRef

60.

Queen MA, Myers AL, Hall M, Shah SS, Williams DJ, Auger KA, et al. Comparative effectiveness of empiric antibiotics for community-acquired pneumonia. Pediatrics. 2014;133(1):e23–9.PubMedPubMedCentralCrossRef

61.

Williams DJ, Hall M, Shah SS, Parikh K, Tyler A, Neuman MI, et al. Narrow vs broad-spectrum antimicrobial therapy for children hospitalized with pneumonia. Pediatrics. 2013;132(5):e1141–8.PubMedPubMedCentralCrossRef

62.

Emery DP, Milne T, Gilchrist CA, Gibbons MJ, Robinson E, Coster GD, et al. The impact of primary care on emergency department presentation and hospital admission with pneumonia: a case-control study of preschool-aged children. NPJ Primary Care Respir Med. 2015;25:14113.CrossRef

63.

Hazir T, Fox LM, Nisar YB, Fox MP, Ashraf YP, MacLeod WB, et al. Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial. Lancet. 2008;371(9606):49–56.PubMedCrossRef

64.••

Breuer O, Blich O, Cohen-Cymberknoh M, Averbuch D, Kharasch S, Shoseyov D, et al. Antibiotic treatment for children hospitalized with community-acquired pneumonia after oral therapy. Pediatr Pulmonol. 2015;50(5):495–502. The only current research evaluating the outcome of community aquired pneumonia in children with prior antibiotic therapy.PubMedCrossRef

Titel: The Impact of Prior Antibiotic Therapy on Outcomes in Children Hospitalized for Community-Acquired Pneumonia
verfasst von: Eran Lavi
Oded Breuer
Publikationsdatum: 01.01.2016
Verlag: Springer US
Erschienen in: Current Infectious Disease Reports / Ausgabe 1/2016
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-015-0509-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The Impact of Prior Antibiotic Therapy on Outcomes in Children Hospitalized for Community-Acquired Pneumonia

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Erhöhte Mortalität bei postpartalem Brustkrebs

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Erhöhte Mortalität bei postpartalem Brustkrebs

Update Innere Medizin